The recently released Proteolysis-targeting chimeric molecules (PROTACs) Market Report 2024, delivers an in-depth analysis of the market. This comprehensive evaluation includes size, product specifications, cost structures, industry connections, and an overview of the market landscape. Additionally, the report offers detailed insights into the Proteolysis-targeting chimeric molecules (PROTACs) market’s size, volume, and forecasts across various product types, applications, and end-users. With its expert insights, the report serves as a crucial guide for enterprises seeking a strategic comprehension of the constantly evolving technology sector.
Who are the Largest Manufacturers of Proteolysis-targeting chimeric molecules (PROTACs) Market Globally?
- AbbVie Inc.
- Arvinas, Inc.
- AstraZeneca plc
- Bayer AG
- Bristol Myers Squibb Company
- C4 Therapeutics, Inc.
- Cullgen Inc.
- Daiichi Sankyo Co., Ltd.
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Kymera Therapeutics, Inc.
- Merck & Co., Inc.
- Nurix Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Proteolix, Inc.
- Progenra, Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Zenith Epigenetics Ltd.Proteolysis-targeting Chimeric Molecules (PROTACs) Market Recent Developments
- In March 2023, Aileron Therapeutics announced the initiation of a Phase 1 clinical trial of its ALRN-6924 ProTac for the treatment of advanced solid tumors. The trial will evaluate the safety and efficacy of the drug in combination with chemotherapy.
- In February 2022, Zentalis Pharmaceuticals announced positive preliminary data from a Phase 1 clinical trial of its ZN-c3 ProTac for the treatment of solid tumors. The trial showed promising safety and efficacy data, with several patients experiencing partial responses.
- In January 2022, Vividion Therapeutics announced a $135 million series D financing round to advance its platform for developing small-molecule protein degraders, including ProTacs. The funds will be used to advance multiple drug candidates into the clinic.
- In December 2021, Kymera Therapeutics announced positive preclinical data for its lead ProTac candidate, KYM-001, for the treatment of solid tumors. The drug demonstrated significant tumor growth inhibition in multiple preclinical models.
- In November 2021, Nurix Therapeutics announced a collaboration with Gilead Sciences to develop novel ProTacs for the treatment of cancer and other diseases. The partnership will leverage Nurix’s expertise in protein degradation and Gilead’s experience in drug development.
Proteolysis-targeting chimeric molecules (PROTACs) Market’s Drivers and Restraints:
The report delves into crucial aspects of the Proteolysis-targeting chimeric molecules (PROTACs) market, including production costs, supply chain dynamics, and raw material dependencies. It offers an analysis of how the COVID-19 pandemic has affected the industry and provides actionable recommendations for businesses to navigate evolving market conditions effectively. Key market restraints, such as economic challenges in emerging nations and obstacles within the business landscape, are identified and explored in detail. Understanding these risks enables businesses to devise strategies aimed at mitigating challenges and ensuring sustained success in this dynamic industry.
Get Sample Report Copy of Proteolysis-targeting chimeric molecules (PROTACs) Market Report
Proteolysis-targeting chimeric molecules (PROTACs) Market Size And Scope
The Proteolysis-targeting chimeric molecules (PROTACs) market has experienced notable growth in recent years, propelled by the rising demand for power electronics across various sectors, including automotive, telecommunications, and renewable energy. This market is poised for further expansion as the global adoption of electric vehicles and renewable energy sources accelerates. Proteolysis-targeting chimeric molecules (PROTACs) s are highly valued for their exceptional thermal conductivity, electrical insulation, and mechanical strength, making them indispensable in power modules and electronic components. With ongoing advancements in technology and manufacturing, the applications of Proteolysis-targeting chimeric molecules (PROTACs) s are expected to broaden, extending their reach into an even wider array of uses in the near future.
Regional Segmentation:
- North America: U.S., Canada and Mexico
- Europe: Germany, France, U.K., Italy, Spain, and Rest of Europe
- Asia Pacific: China, India, Japan, South Korea, Southeast Asia, and Rest of Asia Pacific
- South America: Brazil, Argentina, and Rest of Latin America
- Middle East & Africa: GCC Countries, South Africa, and Rest of Middle East & Africa
Why You Should Purchase This Report:
- Discovering Valuable Connections: Uncover potential suppliers and partnership opportunities highlighted in the report.
- Market Dynamics and Trends: Grasp a complete understanding of the global Proteolysis-targeting chimeric molecules (PROTACs) market’s dynamics and trends.
- In-Depth Market Analysis: Explore the latest market trends and thorough competitive analysis, along with other key insights about the global market.
- Spotting Potential Collaborators: Learn about potential future partners, suppliers, or affiliates outlined in the report.
- Strategic Mergers and Acquisitions: Strategically plan mergers and acquisitions by identifying top manufacturers in the industry.
- Identifying Emerging Competitors: Recognize emerging players who have strong product offerings, allowing you to devise effective strategies to stay competitive.
- Targeting New Clients or Partners: Identify potential new clients or partners within your desired audience.
- Strategizing Based on Industry Leaders: Develop tactical plans by understanding the key areas of focus for leading companies.
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
Our Other Reports:
Sports Medicine Market to Generate a CAGR of 5.6% by 2031, Driven by High Youth Sports Participation
Sports Medicine Market to Generate a CAGR of 5.6% by 2031, Driven by High Youth Sports Participation
Genomics Market is Predicted to Expand at an Impressive 19.4% CAGR through 2031
Genomics Market is Predicted to Expand at an Impressive 19.4% CAGR through 2031
Genomics Market is Predicted to Expand at an Impressive 19.4% CAGR through 2031
Synergy between Medicine and Technological Drives Sports Medicine Market at 5.6% CAGR through 2031